Mannosylated polyethylenimine-cholesterol-based nanoparticles for targeted delivery of minicircle DNA vaccine against COVID-19 to antigen-presenting cells

Eusébio, Dalinda; Paul, Milan; Biswas, Swati; Cui, Zhengrong; Costa, Diana; Sousa, Ângela

doi:10.1016/j.ijpharm.2024.123959

Cited by 3 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approaching the challenge of improving the delivery and immunogenicity of DNA vaccines, specifically against COVID-19, PEI covalently bound to cholesterol (PEI-CHOL) and mannose (PEI-CHOL-MAN) improved cellular uptake, reduced cytotoxicity, and target mannose receptors on APCs; the synthesis involved conjugating PEI with cholesteryl chloroformate, followed by reacting PEI-CHOL with D-mannose in the presence of sodium cyanoborohydride and acetic acid, resulting in NPs approximately 170 nm and 204 nm in size, with zeta potentials around +15 mV; the PEI-CHOL-MAN NPs demonstrated enhanced cellular uptake and significant stimulation of pro-inflammatory cytokine production, indicating improved dendritic cell maturation and a stronger immune response; the NPs exhibited improved biocompatibility with reduced cytotoxicity and demonstrated stability in various media, maintaining their integrity and protecting the encapsulated DNA from degradation; the incorporation of mannose and cholesterol enhanced targeted delivery, transfection efficiency, and safety, making this multifunctional PEI-based NPs formulation a promising approach for enhancing the efficacy of DNA vaccines against COVID-19 and potentially other infectious diseases [161].…”

Section: Cationic Nanostructures In Vaccine Design Against Infectionsmentioning

confidence: 99%

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Preprint

View full text Add to dashboard Cite

Nanovaccines are able to deliver antigen(s) and immunomodulator(s) directly to antigen-presenting cells (APCs) of the lymphatic system. Positive charges improve their uptake by APCs and often drive a Th-1 biased immune response so necessary against infectious diseases caused by intracellular pathogens and cancers. However, cationic compounds often display a dose-dependent toxicity so that systematic evaluation of cytotoxicity against cells in culture is required. After the rapid evolution of nanovaccines against SARS-Covid 2, mRNA vaccines gained much strength and have been designed against several infectious diseases, often relying on cationic components for mRNA protection. Once established the limiting concentration for the cationic compound, cationic nanovaccines perform well eliciting the desired Th-1 improved immune response in most cases. Other valuable approach found in the literature has been the construction of biocompatible nanoparticles (NPs) carrying cationic lipids, polymers or surfactants so that minimization of the concentration for the cationic component led to absence of toxicity. Against cancer, recent constructions of nanovaccines in situ after cancer cell disruption in the presence of adjuvants led to systemic presentation of multiple tumoral antigens yielding, in many instances, prevention of metastasis appearance and conversion of tumors non treatable by immunotherapy into treatable ones.

show abstract

Section: Cationic Nanostructures In Vaccine Design Against Infectionsmentioning

confidence: 99%

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Preprint

View full text Add to dashboard Cite

show abstract

Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review

Pereira,

Tredus,

Corá

et al. 2024

Nanomedicine

View full text Add to dashboard Cite

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Pharmaceutics

View full text Add to dashboard Cite

Cationic vaccines of nanometric sizes can directly perform the delivery of antigen(s) and immunomodulator(s) to dendritic cells in the lymph nodes. The positively charged nanovaccines are taken up by antigen-presenting cells (APCs) of the lymphatic system often originating the cellular immunological defense required to fight intracellular microbial infections and the proliferation of cancers. Cationic molecules imparting the positive charges to nanovaccines exhibit a dose-dependent toxicity which needs to be systematically addressed. Against the coronavirus, mRNA cationic nanovaccines evolved rapidly. Nowadays cationic nanovaccines have been formulated against several infections with the advantage of cationic compounds granting protection of nucleic acids in vivo against biodegradation by nucleases. Up to the threshold concentration of cationic molecules for nanovaccine delivery, cationic nanovaccines perform well eliciting the desired Th 1 improved immune response in the absence of cytotoxicity. A second strategy in the literature involves dilution of cationic components in biocompatible polymeric matrixes. Polymeric nanoparticles incorporating cationic molecules at reduced concentrations for the cationic component often result in an absence of toxic effects. The progress in vaccinology against cancer involves in situ designs for cationic nanovaccines. The lysis of transformed cancer cells releases several tumoral antigens, which in the presence of cationic nanoadjuvants can be systemically presented for the prevention of metastatic cancer. In addition, these local cationic nanovaccines allow immunotherapeutic tumor treatment.

show abstract

Mannosylated polyethylenimine-cholesterol-based nanoparticles for targeted delivery of minicircle DNA vaccine against COVID-19 to antigen-presenting cells

Cited by 3 publications

References 62 publications

Emerging Cationic Nanovaccines

Emerging Cationic Nanovaccines

Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review

Emerging Cationic Nanovaccines

Contact Info

Product

Resources

About